Ysios Capital

Total investments

74

Average round size

41M

Portfolio companies

42

Rounds per year

4.62

Lead investments

16

Follow on index

0.43

Exits

10

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsHospitalManufacturingMedical DeviceMedicalLife SciencePharmaceuticalTherapeutics

Summary

Ysios Capital appeared to be the VC, which was created in 2008. The fund was located in Europe if to be more exact in Spain. The main department of described VC is located in the Barcelona.

The fund was created by Joel Jean Mairet. Besides them, we counted 6 critical employees of this fund in our database.

Deals in the range of 10 - 50 millions dollars are the general things for fund. The high activity for fund was in 2017. Despite it in 2019 the fund had an activity. The fund is generally included in 2-6 deals every year. Opposing the other organizations, this Ysios Capital works on 6 percentage points less the average amount of lead investments. The real fund results show that this VC is 20 percentage points more often commits exit comparing to other companies. The higher amount of exits for fund were in 2014.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Ysios Capital, startups are often financed by Kurma Partners, Caixa Capital Risc, Life Sciences Partners. The meaningful sponsors for the fund in investment in the same round are Life Sciences Partners, Idinvest Partners, Andera Partners. In the next rounds fund is usually obtained by Caixa Capital Risc, Kurma Partners, Gilde Healthcare.

Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Spain. Among the most popular fund investment industries, there are Medical, Hospital. Among the various public portfolio startups of the fund, we may underline CVRx, AM Pharma, BioVex The fund has specific favorite in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low.

Show more

Investments analytics

Analytics

Total investments
74
Lead investments
16
Exits
10
Rounds per year
4.62
Follow on index
0.43
Investments by industry
  • Biotechnology (62)
  • Health Care (39)
  • Medical (32)
  • Pharmaceutical (26)
  • Therapeutics (17)
  • Show 23 more
Investments by region
  • United States (14)
  • Spain (24)
  • Netherlands (8)
  • Denmark (6)
  • France (6)
  • Show 6 more
Peak activity year
2021
Number of Unicorns
2
Number of Decacorns
2

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
12
Avg. valuation at time of investment
81M
Group Appearance index
0.92
Avg. company exit year
9
Avg. multiplicator
5.56
Strategy success index
0.40

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
ADCendo 29 May 2024 Biotechnology Early Stage Venture 18M Capital Region of Denmark, Copenhagen, Denmark
Minoryx Therapeutics 31 May 2022 Biotechnology, Genetics, Medical, Pharmaceutical Late Stage Venture 60M Barcelona, Catalonia, Spain

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.